KYMR vs. SANA, APGE, DNLI, DNA, VCEL, RXRX, FUSN, TWST, BEAM, and INBX
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Sana Biotechnology (SANA), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Ginkgo Bioworks (DNA), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Fusion Pharmaceuticals (FUSN), Twist Bioscience (TWST), Beam Therapeutics (BEAM), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
Kymera Therapeutics (NASDAQ:KYMR) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
Kymera Therapeutics presently has a consensus target price of $41.10, suggesting a potential upside of 6.15%. Sana Biotechnology has a consensus target price of $11.67, suggesting a potential upside of 22.94%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Kymera Therapeutics.
Kymera Therapeutics received 28 more outperform votes than Sana Biotechnology when rated by MarketBeat users. However, 47.83% of users gave Sana Biotechnology an outperform vote while only 47.56% of users gave Kymera Therapeutics an outperform vote.
In the previous week, Kymera Therapeutics had 6 more articles in the media than Sana Biotechnology. MarketBeat recorded 12 mentions for Kymera Therapeutics and 6 mentions for Sana Biotechnology. Kymera Therapeutics' average media sentiment score of 0.28 beat Sana Biotechnology's score of 0.02 indicating that Kymera Therapeutics is being referred to more favorably in the media.
Kymera Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.
Sana Biotechnology has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -194.67%. Kymera Therapeutics' return on equity of -31.92% beat Sana Biotechnology's return on equity.
88.2% of Sana Biotechnology shares are held by institutional investors. 15.8% of Kymera Therapeutics shares are held by insiders. Comparatively, 34.9% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Kymera Therapeutics has higher revenue and earnings than Sana Biotechnology. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Kymera Therapeutics beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
